Lawrence Bruno compensation by year
Core Laboratories Summary Compensation Table · all 5 fiscal years held| Component | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Salary | $820,000 | $820,000 | $886,912 | $886,912 | $886,912 |
| Bonus | $0 | $0 | $0 | $0 | $0 |
| Stock awards | $4,939,861 | $4,873,523 | $6,514,988 | $5,671,781 | $3,505,105 |
| Option awards | $0 | $0 | $0 | $0 | $0 |
| Non-equity incentive | $459,889 | $527,143 | $371,109 | $1,159,321 | $351,217 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 |
| All other | $328,380 | $185,730 | $215,074 | $214,526 | $237,257 |
| Total | $6,548,130 | $6,406,396 | $7,988,083 | $7,932,540 | $4,980,491 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Core Laboratories Inc. DEF 14A filed March 31, 2026, accession 0001193125-26-134986, and prior-year filings.
How this page was built: the Core Laboratories Inc. filed document, accession 0001193125-26-134986. Every figure is read from that document and cited to the page and table it appears in. Filed March 31, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| PSU | 764,554 | $12,255,801 | — |
Per the Outstanding Equity Awards at Fiscal Year-End table in Core Laboratories Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Change-in-control & termination
estimated payments Core Laboratories discloses, by trigger · FY2025| Trigger | Cash severance | Accelerated equity | Benefits continuation | Total as disclosed |
|---|---|---|---|---|
| Voluntary resignation | $0 | $0 | $717,300 | $717,300 |
| Disability | $0 | $12,255,801 | $0 | $12,255,801 |
| Change in control and involuntary termination | $5,321,472 | $12,255,801 | $717,300 | $19,206,485 |
| Involuntary for cause | $0 | $0 | $0 | $0 |
| Death | $0 | $12,255,801 | $0 | $12,255,801 |
| Involuntary termination without cause | $1,773,824 | $12,255,801 | $717,300 | $15,658,837 |
Per the Potential Payments Upon Termination or Change in Control table in Core Laboratories Inc.'s FY2025 proxy. Estimates as the company printed them; a dash means it printed no figure.
Core Laboratories’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Lawrence Bruno · this page | Chairman, President and Chief Executive Officer | $4,980,491 |
| Christopher Hill | Senior Vice President, and Chief Financial Officer | $1,858,243 |
| Mark Tattoli | Senior Vice President, Secretary and General Counsel | $1,145,696 |
| Gwendolyn Gresham | Senior Vice President, Corporate Development and Investor Relations | $1,143,503 |
Board service
Core Laboratories board · FY2023–FY2025How this board is paid
Company policy: Core Laboratories pays directors a $75,000 cash retainer and $150,000 in equity. As stated in Core Laboratories's FY2025 proxy.
The full Core Laboratories compensation record
free company briefThis page is one person within Core Laboratories's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Core Laboratories proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Core Laboratories's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Core Laboratories's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.